title: Large-volume intrathecal enzyme delivery increases survival of a mouse model of late infantile neuronal ceroid lipofuscinosis.
abstract: Late infantile neuronal ceroid lipofuscinosis (LINCL) is a progressive neurodegenerative lysosomal storage disorder caused by mutations in TPP1, the gene encoding the lysosomal protease tripeptidyl-peptidase (TPP1). LINCL primarily affects children, is fatal and there is no effective treatment. Administration of recombinant protein has proved effective in treatment of visceral manifestations of other lysosomal storage disorders but to date, only marginal improvement in survival has been obtained for neurological diseases. In this study, we have developed and optimized a large-volume intrathecal administration strategy to deliver therapeutic amounts of TPP1 to the central nervous system (CNS) of a mouse model of LINCL. To determine the efficacy of treatment, we have monitored survival as the primary endpoint and demonstrate that an acute treatment regimen (three consecutive daily doses started at 4 weeks of age) increases median lifespan of the LINCL mice from 16 (vehicle treated) to 23 weeks (enzyme treated). Consistent with the increase in life-span, we also observed significant reversal of pathology and improvement in neurological phenotype. These results provide a strong basis for both clinical investigation of large-volume/high-dose delivery of TPP1 to the brain via the cerebrospinal fluid (CSF) and extension of this approach towards other neurological lysosomal storage diseases.
authors: Center for Advanced Biotechnology and Medicine, Piscataway, New Jersey 08854, USA. lobel@cabm.rutgers.edu
authors: Su
authors: S
authors: Xu
authors: Lingling
authors: L
authors: Wang
authors: Mukarram
authors: M
authors: El-Banna
authors: Istvan
authors: I
authors: Sohar
authors: David E
authors: DE
authors: Sleat
authors: Peter
authors: P
authors: Lobel
mesh_terms: D000626:Aminopeptidases / Q000008:administration & dosage* / Q000235:genetics / Q000627:therapeutic use; D000818:Animals; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases / Q000008:administration & dosage* / Q000235:genetics / Q000627:therapeutic use; D004195:Disease Models, Animal; D007278:Injections, Spinal; D051379:Mice; D009472:Neuronal Ceroid-Lipofuscinoses / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000235:genetics / Q000627:therapeutic use; D057057:Serine Proteases / Q000008:administration & dosage* / Q000235:genetics / Q000627:therapeutic use; D000091346:Tripeptidyl-Peptidase 1
chemical_list: D011994:Recombinant Proteins; C000717268:Tpp1 protein, mouse; D000091346:Tripeptidyl-Peptidase 1; D057057:Serine Proteases; D000626:Aminopeptidases; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases